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ORIGINAL RESEARCH
Background: Rates of coronary heart disease (CHD) mortality are 40% higher amongst
South Asian men and women living in the UK compared with the general UK population.
Despite an established excess CHD risk, little is known of the efficacy and safety of 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) amongst South Asian
migrants.
Methods and results: Hyperlipidemic South Asian patients (raised or uncontrolled low-
density lipoprotein cholesterol [LDL-C]) were recruited from two UK centers (n = 33). After
a five-week period, which included dietary advice, patients received atorvastatin 10 mg/d for
five weeks to achieve a target LDL-C goal of < 3.0 mmol/L, titrated to 20 mg, 40 mg, or 80 mg
for a further 12 weeks as required. Significant reductions in LDL-C levels from baseline were
observed after 4 weeks’ and 17 weeks’ treatment with atorvastatin (≥ 33.6%; 26.0, 41.2).
Overall, 81% (95% confidence interval [CI]: 62.5, 92.6%) achieved the target LDL-C after
4 weeks’ treatment with 10 mg atorvastatin. Titration to a dose of more than 20 mg was required
in only one patient (40 mg) at any point during the study. Nineteen patients reported at least
one adverse event during the study; the majority were mild in severity and considered unrelated
to atorvastatin.
Conclusions: Atorvastatin was effective in achieving target lipid levels and was well tolerated.
Statin therapy for high-risk South Asian individuals is likely to benefit CHD outcomes, although
further and larger prospective trials are required.
Keywords: hyperlipidemia, lipids, cholesterol, dyslipidemia, statins, coronary heart disease,
South Asians
Introduction
Coronary heart disease (CHD) is indiscriminately common to the global diaspora of
people who originate from the Indian subcontinent (South Asia). Despite varied
geographical origins, preserved customs, and adopted lifestyles in host countries
(Shaunak et al 1986), CHD mortality is consistently reported as exceptionally high
amongst South Asian migrants compared with indigenous populations (Derry et al
1987; Miller et al 1989; McKeigue et al 1989; Chadha et al 1993; Balarajan 1995).
Migrants living in the UK consistently show markedly higher CHD mortality rates
compared with the general UK population (Gill et al 2002).
Cross-sectional studies from the UK suggest that serum cholesterol is not
particularly high among South Asians compared with the general population (Whitty
et al 1999). However, preferred studies of prospective design confirm that established
CHD risk factors such as serum cholesterol do operate among South Asian populations
(Miller 1989; Chadha et al 1993; Lee et al 2001). Moreover, the risk from serum
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cholesterol has been shown to increase with migration to
the UK among migrants from the Punjab (Bhatnagar et al
1995) and Gujarat, India (Patel et al 2005).
Overwhelming evidence from primary and secondary
prevention trials have demonstrated that lipid-lowering
intervention can lower the incidence of CHD.
Pharmacological intervention trials using 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase
inhibitors (statins) have established that lowering low-
density lipoprotein cholesterol (LDL-C) levels will lead to
a substantial reduction in the risk of CHD events
(Scandinavian Simvastatin Survival Group 1994; Heart
Protection Study Collaborative Group 2002; Sever et al
2003).
Atorvastatin is a well established member of the statin
class that has demonstrated tolerability, efficacy, and safety
in the treatment of hypercholesterolemia in preclinical and
clinical studies (Black et al 1998; Jones et al 1998). However,
the uptake of statin therapy in South Asian patients is
reportedly lower than in other populations (Patel et al 2002),
and information relating to the efficacy of statin use is scarce.
This open label, noncomparative, two center pilot study
provides a basis for further studies in this high-risk patient
population. The primary objective was to achieve target
lipid-lowering goals as defined by the Joint British
Guidelines (JBG) on prevention of CHD in clinical practice
(British Cardiac Society et al 2000). A secondary objective
of the study was to assess the feasibility of conducting a
multicenter study among this undertreated group of patients
by testing ideas that will help to recruit and retain patients
in clinical studies.
Methods
Study design
Patients were recruited over a one-year period from two
sites in the UK and underwent a 5-week dietary period of
study (dietary counseling and withdrawal of existing lipid-
lowering therapy). Baseline total cholesterol and LDL-C
levels were determined at week 4 of the dietary period, and
those with LDL-C ≥ 3.0 mmol/L received atorvastatin 10 mg/
day for 5 weeks. The lipid profile was reassessed after 4
weeks to determine whether the dose of atorvastatin needed
to be titrated to 20 mg/d, 40 mg/d, or 80 mg/d. The treatment
period continued for a further 12 weeks. Recruitment
continued until 30 evaluable patients were enrolled. A local
research ethics committee at both investigational sites
reviewed the study protocol and its amendments. All patients
gave written informed consent prior to enrollment. A patient
information sheet written in English, Hindi, and Urdu, was
provided to all patients before signed consent was given.
To be eligible for inclusion, patients had to be of South
Asian ethnic origin (defined as both parents originating from
the Indian subcontinent), male or female aged 18–80 years,
have hyperlipidemia, and fulfil at least one of the following
criteria:
￿ Currently receiving lipid-lowering therapy that did not
adequately control their dyslipidemia (total cholesterol
≥ 5.0 mmol/L [190 mg/dL], LDL-C ≥ 3.0 mmol/L).
￿ Currently receiving or had previously received lipid-
lowering therapy that either they or their physician
considered unacceptable.
￿ Were not receiving lipid-lowering therapy, but had
elevated serum cholesterol and LDL-C levels that met
the criteria for lipid-lowering therapy.
Major exclusion criteria included the following:
uncontrolled hypertension; unsatisfactory glycemic control
defined by hemoglobin A1c > 9%; hepatic dysfunction;
creatine phosphokinase levels > 3 times the upper limit of
normal; use of any drugs known to affect lipid levels (eg,
systemic steroids), immunosuppressive agents, or drugs
associated with rhabdomyolysis in combination with statins
(eg, cyclosporin, erythromycin).
Evaluation of efficacy
The primary analysis of efficacy was the change in LDL-C
from baseline to 4 weeks’ and 17 weeks’ treatment, and the
proportion of patients who achieved the target LDL-C level
of < 3.0 mmol/L after 4 weeks’ and 17 weeks. Secondary
efficacy measures were the changes from baseline in high-
density lipoprotein cholesterol (HDL-C), total cholesterol,
total cholesterol/HDL-C ratio, triglycerides, apolipoprotein
AI (Apo-AI), and apolipoprotein B (Apo-B) after 4 weeks’
and 17 weeks’ treatment.
Evaluation of safety
Adverse events were defined as any unfavorable and
unintended sign (including an abnormal laboratory finding),
symptom, or disease temporarily associated with the use of
a medicinal product, whether or not related to the product.
The relationship of an adverse event to atorvastatin and the
intensity of an adverse event were assessed by the
investigator.
Treatment-emergent adverse events were defined as
those not reported during screening, or at baseline, or notVascular Health and Risk Management 2005:1(4) 353
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recorded as continuing on medical history, or any event that
had worsened relative to screening, baseline, or medical
history.
Serious adverse events were defined as: those that were
fatal; life threatening; required hospitalization (new or long-
term); resulted in persistent or significant disability; or
resulted in a congenital anomaly/birth defect. Jaundice and
myopathy were considered serious adverse events for the
purposes of this study. Clinical laboratory determinations,
including aspartate aminotransferase, alanine amino-
transferase, and creatine phosphokinase, were performed
at each clinic visit.
Compliance
Treatment compliance was assessed according to the number
of tablets returned after 5 weeks’ and 17 weeks’ treatment.
Patients were considered to be protocol violators if they
had taken less than 70% of the study medication.
Statistical methods
We hypothesised that a significant proportion of
hyperlipidemic patients would achieve target LDL
cholesterol with 4 weeks’ and 17 weeks’ atorvastatin therapy.
Based on measures from a Caucasian population (März et
al 1999), we calculated a total of 33 patients would be
sufficient to observe a comparable proportion (67%) of
South Asian patients achieving target LDL-C using a two-
sided test with a power of 80%, α < 0.05. We aimed to screen
dyslipidemic South Asian patients in excess (double) of this
number to allow for poor recruitment into the study. The
intent-to-treat (ITT) population was used for safety
evaluations and was defined as all patients who received at
least one dose of atorvastatin. Changes from baseline in lipid
measures were determined using a last observation carried
forward (LOCF) analysis where there were missing values.
Data are reported as mean absolute change and mean percent
change from baseline, together with 95% confidence
intervals (CI). All lipid outcomes were assessed using a
paired t-test, with the exception of serum triglycerides, for
which a Wilcoxon signed rank test was performed due to a
skew from the normal distribution in the dataset.
Results
Patient population and baseline
characteristics
Fifty-six patients were screened, of whom 33 received
atorvastatin (10 mg/d), and were subsequently included in
the safety analysis. Twenty-two patients (67%) had primary
risk factors for CHD, of whom 16 had no established CHD
or peripheral vascular disease. Thirty-one patients were
included in the modified ITT population. Ten patients
discontinued from the study prematurely (four due to adverse
events, three due to noncompliance with atorvastatin, and
three lost to follow-up). Mean age (standard deviation [± SD])
of patients was 52.2 (± 10.0) years for men (n = 24) and 60.9
(± 7.4) years for women (n = 9). The mean duration of
dyslipidemia since initial diagnosis was 1.6 (± 2.3) years.
Twenty-nine patients reported at least one concomitant
disease at time of entry into the study, the most common of
which were hypertension (39%) and diabetes (30%).
Table 1 Treatment-emergent AEs by body system in patients
treated with atorvastatin (n = 33)
Causality
Patients with (number of events)
 at least one Not
Body system  event (%) Related related
Body as a whole 11 2 13
Cardiovascular 1 0 1
Digestive 3 1 3
Hemic and lymphatic 1 0 1
Metabolic and nutritional 4 1 3
Musculoskeletal 4 2 3
Nervous 4 0 4
Respiratory 1 0 1
Skin and appendages 2 0 2
Abbreviations: AEs, adverse events.
Figure 1 Mean percent change from baseline in lipid measures after 4 weeks’
treatment with atorvastatin 10 mg/d (n = 31 for all measures).
Abbreviations: LDL-C, low-density lipoprotein cholesterol; HDL-C, high-
density lipoprotein cholesterol; Apo, apolipoprotein.
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Efficacy
After 4 weeks’ treatment with atorvastatin 10 mg/d, a
significant reduction in LDL-C levels from baseline was
observed (–1.6 mmol/L; 95% CI –1.9  to  –1.4; p < 0.0001).
This represented a mean reduction of 40.1% (95% CI 45.2–
35.0) from baseline (Figure 1). Eighty-one percent (95%
CI 62.5–92.6) of patients achieved the target LDL-C level
(< 3.0 mmol/L) after 4 weeks’ treatment with atorvastatin
10 mg/d (Figure 2).
After 17 weeks’ treatment with atorvastatin 10 mg/d–
40 mg/d, a significant reduction in LDL-C levels from
baseline was observed (–1.4 mmol/L; 95% CI –1.7  to  –1.0;
p < 0.0001); a mean reduction of 33.6% (95% CI –41.2 to  
–26.0) (Figure 3). Titration from 10 mg/d to 40 mg/d
atorvastatin enabled 71% (95% CI 52.0–86.8) of patients
to achieve target LDL-C level after 17 weeks’ treatment
(Figure 2). Titration to a dose of more than 20 mg/d was
required in only one patient (40 mg/d) at any point during
the study. For the secondary analyses of efficacy, significant
reductions from baseline were observed after 4 weeks’ and
17 weeks’ treatment with atorvastatin for total cholesterol,
total cholesterol/HDLC ratio, Apo-B, and triglycerides.
HDL-C and Apo-AI levels increased from baseline over the
same time period, but did not reach statistical significance
(Figures 1 and 3). Between study entry and baseline (week
4 of the dietary run-in period) there was an increase in
mean ± SD LDL-C levels from 3.73 (± 0.94) mmol/L – 4.07
(± 0.73) mmol/L. However, at week 5 of the dietary period,
mean LDL-C had returned to the screening levels (3.76
[0.76] mmol/L). When week 5 of the dietary period was used
as the baseline assessment, similar significant reductions
were still observed after 4 weeks and 17 weeks of treatment.
Recruitment
Recruitment was poor at both centres; the majority of
patients (18) were enrolled at the Sandwell Healthcare NHS
Trust. Both centres employed staff of Asian origin to aid
recruitment. The response rate was 33% from a target
population of 283 referrals.
Safety
Of a total of 33 patients, five patients required a dose of
atorvastatin > 10 mg/d (four patients received 20 mg/d and
one patient 40 mg/d). The theoretical duration of treatment
was 119 days (17 weeks). Almost 90% of patients (29/33)
received atorvastatin for at least 91 days. Nineteen patients
(58%) reported at least one treatment-emergent adverse
event. The majority of treatment-emergent adverse events
were mild in severity and considered unrelated to
atorvastatin treatment; the most common being headache
(7 patients), myalgia (4 patients), and back pain (3 patients).
There were no deaths or serious adverse events reported,
and no laboratory results were considered to be clinically
significant. Five patients reported adverse events that
resulted in discontinuation of atorvastatin therapy and four
of these patients withdrew from the study.
Discussion
Atorvastatin was an effective and well tolerated treatment
for lowering total cholesterol, LDL-C, triglycerides, and
Apo-B in this cohort of South Asian patients with
Figure 2 Percent of patients achieving Joint British Guidelines (JBG) target
LDL-C and total cholesterol levels after 4 weeks’ treatment with 10 mg/d and
17 weeks’ treatment with 10–40 mg/d atorvastatin.
Figure 3 Mean percent change from baseline in lipid measures after 17 weeks’
treatment with atorvastatin 10 mg/d–40 mg/d (n = 31 for all measures).
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dyslipidemia, while causing no significant changes in HDL-
C and Apo-A. The majority of patients (81%) achieved JBG
target levels of LDL-C within the initial 4 weeks of
atorvastatin treatment. Titration between 10 mg/d and
40 mg/d of atorvastatin resulted in 71% of patients achieving
JBG target levels after 17 weeks’ treatment; however, all
patients achieved target levels at some point during the study.
Furthermore, for most patients, it was not necessary to
increase the dose of atorvastatin in order to achieve these
target levels. The percentage reduction in LDL-C in this
study is consistent with previous reports (Black et al 1998)
following treatment with doses of atorvastatin up to 80 mg/d.
Recruitment of these South Asian origin patients was
challenging and a period of one year was required to recruit
the 33 patients for the study. The difficulty in CHD risk
assessment in South Asians is likely due to different attitudes
and knowledge of risk factors for CHD compared with the
general UK population, combined with language barriers
(Gill et al 2002). In Sandwell, South Asian-origin
community healthcare staff were enlisted to educate and
promote initial interest amongst a close-knit Indian Gujarati
group. This culturally sensitive approach was the most
successful for patient participation in this study: one-third
of all patients were generated from the same Gujarati
neighborhood. Similarly, a community link worker of Asian
background at Whipps Cross helped to facilitate recruitment,
but almost all patients enrolled were from the cardiac clinic.
Whole communities were targeted using an approach
that included presentations on CHD within community
centres. This allowed the concept of volunteering for clinical
research to be debated within a broad forum, and
employment of a nurse from the same community was likely
to have benefited compliance with the study. One-on-one
interaction between the study nurse and patient meant that
sensitive cultural issues were aired freely with a good
understanding between both parties. Interpreter services may
not have instilled the same confidence amongst patients.
The broad range of dialects and customs from the Indian
subcontinent limits the value of Indian-origin healthcare staff
to particular migrant populations. While the inclusion of
culture-specific cohorts restricts epidemiological extrapola-
tion, it avoids the danger of generalization. Inference from
this particular study is limited as the South Asian cohort
combines different religions, cultures, diets, and geo-
graphical origins. This preliminary work has nonetheless
highlighted issues that need to be addressed by a more
ambitious investigation.
Cross-sectional analysis against the general UK
population suggests that serum cholesterol is not an obvious
risk amongst people of South Asian origin (McKeigue et al
1989). Nonetheless, serum cholesterol has been shown to
have a causal relationship with incident CHD amongst
Indian migrants and residents in India (Miller et al 1989;
Chadha et al 1993; Lee et al 2001). Therefore, while patients
do not have elevated LDL-C, the target threshold may not
be appropriate for this population, who commonly manifest
with high CHD risk. In this study, 30% of all patients were
diabetic and 39% were hypertensive. There was a reduction
in serum triglycerides after 4 weeks’ statin intervention
(~17%) as well as Apo B (~26%). Although these reductions
in triglycerides and apolipoproteins appear quite marked, it
would be difficult to compare these data with those from
larger trials. Reductions in these risk factors may prove an
important intervention for CHD amongst South Asians. It
is important to follow up the Apo B and triglyceride lowering
effects of atorvastatin with quantitative data on LDL density
in a South Indian migrant population.
Conclusion
Atorvastatin therapy was effective and well tolerated in
treating this population of South Asian patients with
hyperlipidemia to LDL-C goals. Considering that these
patients are at a relatively higher risk of CHD than their
age- and sex-matched European counterparts, it is all the
more important that modifiable CHD risk factors, such as
hypercholesterolemia, are effectively and aggressively
treated, and atorvastatin appears to be both safe and effective
in this regard. However, the difficulties reported in recruiting
patients for this pilot study highlight the challenges to
overcome so that patients can be recruited for any future
large multicenter trial in the South Asian population.
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